Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PDL on the block

PDLI said its board of directors decided to actively seek offers to acquire

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE